JP2023519140A5 - - Google Patents
Info
- Publication number
- JP2023519140A5 JP2023519140A5 JP2022552336A JP2022552336A JP2023519140A5 JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5 JP 2022552336 A JP2022552336 A JP 2022552336A JP 2022552336 A JP2022552336 A JP 2022552336A JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- double
- stranded
- inhibitory rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003756.0 | 2020-03-16 | ||
| GBGB2003756.0A GB202003756D0 (en) | 2020-03-16 | 2020-03-16 | Antagonist of PCSK9 |
| GBGB2010276.0A GB202010276D0 (en) | 2020-07-03 | 2020-07-03 | PCSK9 antagonist |
| GB2010276.0 | 2020-07-03 | ||
| GBGB2013998.6A GB202013998D0 (en) | 2020-09-07 | 2020-09-07 | Antagonist of pcsk9 |
| GB2013998.6 | 2020-09-07 | ||
| GBGB2020553.0A GB202020553D0 (en) | 2020-12-23 | 2020-12-23 | Antagonist of pcsk9 |
| GB2020553.0 | 2020-12-23 | ||
| PCT/EP2021/056540 WO2021185765A1 (en) | 2020-03-16 | 2021-03-15 | Antagonist of pcsk9 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519140A JP2023519140A (ja) | 2023-05-10 |
| JP2023519140A5 true JP2023519140A5 (https=) | 2024-03-15 |
Family
ID=75111564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552336A Ceased JP2023519140A (ja) | 2020-03-16 | 2021-03-15 | Ｐｃｓｋ９のアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230183694A1 (https=) |
| EP (1) | EP4081642A1 (https=) |
| JP (1) | JP2023519140A (https=) |
| CN (1) | CN115066498A (https=) |
| CA (1) | CA3167849A1 (https=) |
| GB (1) | GB2594788B (https=) |
| WO (1) | WO2021185765A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| GB202020534D0 (en) * | 2020-12-23 | 2021-02-03 | Argonaute Rna Ltd | Conjugate |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041508A2 (en) * | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| GB2618915B (en) * | 2022-05-18 | 2024-08-14 | Argonaute Rna Ltd | Treatment of cardiovascular disease |
| CN117106781B (zh) * | 2023-10-16 | 2024-03-22 | 深圳市茵冠生物科技有限公司 | 修饰的核酸及其产品和应用 |
| CN118147134B (zh) * | 2023-11-06 | 2025-02-25 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN117384907B (zh) * | 2023-12-11 | 2024-03-29 | 上海鼎新基因科技有限公司 | 抑制PCSK9表达的siRNA分子及其应用 |
| WO2025252223A1 (zh) * | 2024-06-07 | 2025-12-11 | 迈威(上海)生物科技股份有限公司 | 一种抑制PCSK9基因表达的RNAi制剂及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004261002A (ja) * | 2003-01-08 | 2004-09-24 | Tsutomu Suzuki | ｓｉＲＮＡの製造方法 |
| EP1891216B1 (en) * | 2005-05-25 | 2012-02-22 | The University Of York | Hybrid interfering rna |
| CN101484588B (zh) * | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| CN200950065Y (zh) | 2006-05-24 | 2007-09-19 | 王锦峰 | 一种半自动夹板装置 |
| CA2658183A1 (en) | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| CA2713379A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
| WO2009114475A2 (en) * | 2008-03-09 | 2009-09-17 | Intradigm Corporation | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use |
| WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| JP5894913B2 (ja) * | 2009-06-15 | 2016-03-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ |
| WO2011028938A1 (en) * | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| EP2562257A4 (en) * | 2010-04-19 | 2014-10-01 | Riken | PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS |
| WO2012058693A2 (en) | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| HUE048738T2 (hu) * | 2013-06-27 | 2020-08-28 | Roche Innovation Ct Copenhagen As | Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg |
| CN108348541A (zh) | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| EP4397311A3 (en) | 2016-10-18 | 2024-10-16 | Novartis AG | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
| JP7191101B2 (ja) * | 2017-12-26 | 2022-12-16 | アーゴーナ ファーマシューティカルズ リミテッド | ＰＣＳＫ９遺伝子の発現を抑制するｓｉＲＮＡ分子及びその応用 |
| CN109957565B (zh) * | 2017-12-26 | 2023-04-07 | 广州市锐博生物科技有限公司 | 一种修饰的siRNA分子及其应用 |
| CN118147134B (zh) * | 2023-11-06 | 2025-02-25 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
-
2021
- 2021-03-15 CN CN202180013447.0A patent/CN115066498A/zh active Pending
- 2021-03-15 US US17/908,225 patent/US20230183694A1/en not_active Abandoned
- 2021-03-15 JP JP2022552336A patent/JP2023519140A/ja not_active Ceased
- 2021-03-15 CA CA3167849A patent/CA3167849A1/en active Pending
- 2021-03-15 WO PCT/EP2021/056540 patent/WO2021185765A1/en not_active Ceased
- 2021-03-15 EP EP21712703.4A patent/EP4081642A1/en not_active Withdrawn
- 2021-03-16 GB GB2103594.4A patent/GB2594788B/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519140A5 (https=) | ||
| Kaur et al. | Thermodynamic, counterion, and hydration effects for the incorporation of locked nucleic acid nucleotides into DNA duplexes | |
| RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
| JP2022537987A5 (https=) | ||
| JP6082796B2 (ja) | 遺伝子発現と疼痛 | |
| US8962582B2 (en) | PKR activation via hybridization chain reaction | |
| JP2024531728A5 (https=) | ||
| JP2006515277A5 (https=) | ||
| JP2006502694A5 (https=) | ||
| JP2024535888A5 (https=) | ||
| JP2009532392A5 (https=) | ||
| JP2018525030A5 (https=) | ||
| JP2012050438A5 (https=) | ||
| RU2005133711A (ru) | Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины | |
| RU2007134212A (ru) | Аптамерные терапевтические средства, применимые для лечения связанных с комплементом расстройств | |
| JP2010533171A5 (https=) | ||
| JP2005517436A5 (https=) | ||
| JP2006500958A5 (https=) | ||
| JP2010512747A5 (https=) | ||
| JP2024500036A5 (https=) | ||
| Imbert et al. | Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease | |
| JP2006502243A5 (https=) | ||
| CN118984717A (zh) | Arnatar化合物和用于增强细胞摄取的方法 | |
| JPWO2005030960A1 (ja) | ステイプル型オリゴヌクレオチドおよびそれからなる医薬 | |
| JP2025542331A (ja) | 新規ｒｎａ治療薬及びその使用 |